TORONTO, Feb. 4, 2021 /CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement...
Researchers from ±«ÓãÖ±²¥ have discovered, for the first time, one of the possible mechanisms that contributes to the ability of lysergic acid diethylamide (LSD) to increase social...
RSS